Editor's Note An electronic health record (EHR)-based nudge could significantly reduce low-value axillary surgeries in older women with early-stage breast cancer, researchers reported July 17 in JAMA Surgery. Conducted across eight clinical settings, the initiative significantly cut the rates of low-value sentinel lymph node biopsies (SLNB) by nearly 50% over…
Editor's Note Medical professionals have long accepted that bilateral mastectomy does not improve survival outcomes for breast cancer patients. However, a study published in JAMA Oncology reveals a puzzling finding: Those who develop a second cancer in the other breast have a higher risk of death. As detailed in a…
When it comes to the adoption of artificial intelligence (AI) in medicine, radiology is leading the charge. As of May 13, 2024, the US Food and Drug Administration (FDA) had approved nearly 900 AI- and machine learning (ML)-enabled devices, and the vast majority of them are in radiology. One example…
Editor's Note Artificial intelligence (AI)-fueled analysis of electronic health records suggests that clinical guidelines for de-escalating surgery should be extended to younger breast cancer patients. Conducted by University of Pittsburgh and UPMC Hillman Cancer Center researchers and published in JCO Clinical Cancer Informatics, the analysis suggests that “surgery involving sentinel…
Editor's Note An AI model that outperformed MRI and ultrasound in identifying patients with axillary breast cancer metastasis shows the technology’s potential to reduce the need for needle or surgical biopsies, according to developers at UT Southwestern Medical Center. In a May 21 report on their new AI model, researchers…
Editor's Note The US Food and Drug Administration (FDA) has designated the recall of Hologic Inc.’s BioZorb Marker a class 1, indicating a risk of serious injury or death. BioZorb is an implantable radiographic marker used to mark soft tissue (such as breast tissue) for future medical procedures. Provided sterile…
Editor's Note The US Food and Drug Administration (FDA) approved Lumisight (pegulicianine), a fluorescent imaging drug used to detect cancerous tissue during lumpectomy, on April 17. Administered intravenously prior to surgery, Lumisight is designed for use with the Lumicell Direct Visualization System (DVS) or another imaging device that is FDA-approved…
Editor's Note Researchers from the University of Waterloo have devised a new, noninvasive method for detecting early stage breast cancer in just 2 minutes using very low electro-magnetic frequencies. The findings were first published in August in the Nature journal Scientific Reports. The research team discovered that very low electro-magnetic…
Editor's Note A new artificial intelligence (AI) tool has shown to accurately identify invasive breast cancer patients who are likely to be long-term survivors and could benefit from reduced chemotherapy, according to a new study. The findings were published in Nature Medicine on November 27. Researchers from Northwestern University collaborated…
Editor's Note Online breast cancer surgery information is often difficult to understand and may be impeding people’s ability to make informed decisions about their care, US News October 25 reports. Researchers reviewed patient education materials describing breast-conserving surgery, mastectomy, and lymph node surgery from US National Cancer Institute related websites…